SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma soars on getting USFDA nod for generic Mesalamine extended release capsules

13 May 2022 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 873.10, up by 22.95 points or 2.70% from its previous closing of Rs. 850.15 on the BSE.

The scrip opened at Rs. 850.60 and has touched a high and low of Rs. 881.40 and Rs. 850.60 respectively. So far 23822 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 966.90 on 29-Apr-2022 and a 52 week low of Rs. 652.75 on 18-Jun-2021.

Last one week high and low of the scrip stood at Rs. 891.00 and Rs. 835.25 respectively. The current market cap of the company is Rs. 203979.46 crore.

The promoters holding in the company stood at 54.48%, while Institutions and Non-Institutions held 34.46% and 11.06% respectively.

Sun Pharmaceutical Industries has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic Mesalamine Extended Release Capsules, 500 mg. The generic product approval is based on Pentasa Extended Release Capsules, 500mg as a reference product. Pentasa Extended Release Capsules, 500mg had annualized sales of approximately $213 million in USA. 

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Inds. Share Price

1673.60 -1.60 (-0.10%)
20-Apr-2026 11:22 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1673.60
Dr. Reddys Lab 1237.20
Cipla 1235.85
Zydus Lifesciences 941.30
Lupin 2323.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×